A carregar...
Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?
The current therapy for depression is less than ideal with remission rates of only 25–35% and a slow onset of action with other associated side effects. The persistence of anhedonia originating from depressed dopaminergic activity is one of the most treatment-resistant symptoms of depression. Theref...
Na minha lista:
| Publicado no: | Future Med Chem |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Science Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4976848/ https://ncbi.nlm.nih.gov/pubmed/26619226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4155/fmc.15.134 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|